Last updated
Tianjin Pharmaceutical Da Ren Tang Group: Partnership
Chinese traditional medicine maker Tianjin Pharmaceutical Da Ren Tang Group announced an international randomized, double-blind, controlled clinical trial of its flagship heart remedy Suxiao Jiuxin Pills in collaboration with Singapore General Hospital. Described as the first clinical trial of a Chinese proprietary medicine at a major Western-medicine hospital in Singapore.
Source: discovered:vir.com.vn
- What happened
- Chinese traditional medicine maker Tianjin Pharmaceutical Da Ren Tang Group announced an international randomized, double-blind, controlled clinical trial of its flagship heart remedy Suxiao Jiuxin Pills in collaboration with Singapore General Hospital. Described as the first clinical trial of a Chinese proprietary medicine at a major Western-medicine hospital in Singapore.
- Who
- Tianjin Pharmaceutical Da Ren Tang Group · Singapore
- When
- 2026-10-22
- Source
- discovered:vir.com.vn
- So what
- Alliances broaden the commercial surface, and the leadership need follows.
The leadership read
Alliances broaden the commercial surface, and the leadership need follows. Tianjin Pharmaceutical Da Ren Tang Group's partnership in the sector widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Asia, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.
Market context: The wider read — a Talent Market Index of 109 (Hot), up 7.3 month-on-month — shows Asia signal flow rising (+2.7pts).
Tianjin Pharmaceutical Da Ren Tang Group: 1 signal in the last 90 days.
MitchelLake in this thematic
More signals across Asia
Partnership · Asia
Quant Group →China's Quant Group signed a framework deal for AI robots to be deployed at showrooms for reception, vehicle presentations and sales lead capture.
Partnership · Asia
SingHealth →SingHealth is joining the Cambridge-led BloodCounts! AI blood-test consortium alongside NUHS.
Partnership · Asia
Gilead Sciences →Gilead agreed to pay Shanghai-based PepStar Therapeutics US$1.275B upfront for global rights to HCXT-2001, an experimental oral IL-23 receptor inhibitor in Phase I, as a licensing deal that strengthens its IBD pipeline.
Partnership · Asia
Subic EnerZone →Subic Bay Metropolitan Authority (SBMA) and Subic EnerZone renewed their partnership, extending management and operation of the Subic Bay Freeport Zone power distribution utility for 25 years.
Partnership · Asia
Insolation Energy Ltd. (INA Solar) →INA Solar signed a five-year strategic partnership with US-based Caelux Corp. to commercialize 3 GW of perovskite-silicon hybrid-tandem solar modules combining Caelux's power-generating glass with INA's n-type TOPCon platform, targeting commercial production with up to 29% efficiency by 2028.
Partnership · Asia
QClairvoyance Quantum Labs →QClairvoyance Quantum Labs signed an MoU with Ramdeobaba University (Nagpur) to set up a quantum software lab and a quantum communication hardware lab on campus, with two professionals deployed for 12 months, faculty training, and joint research and internships.
Where this lands in our work
- Cross Border Expansion Executive Search →
Partnerships are usually the first structure a company builds before it hires locally.
- Executive Search: Asia →
Our Asia practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗